Physiologically relevant in vitro retinal models for ophthalmology drug discovery and safety testing
We strengthened our leadership in ophthalmology with the acquisition of Newcells Biotech’s ophthalmology business, expanding our portfolio and supporting our mission to deliver more physiologically relevant in vitro retinal models for ophthalmology drug discovery and safety testing.
Our new ebook outlines key in vitro systems for retinal disease modeling and toxicology assessment using human iPSC‑derived cells.
- axoCells™ human iPSC‑derived RPE cells: pure RPE cells produced at scale, with functionality assessed through phagocytosis and TEER
- axoCells™ human iPSC‑derived microglia: expressing canonical microglia markers and showing reproducible responses to pro‑inflammatory signals
- Human iPSC‑derived retinal organoids: extensively characterized organoids that provide a human‑derived platform for retinal toxicity studies
We provide a high‑throughput and high‑content model for dry AMD that applies relevant stressors to reproduce key disease features in vitro. The high‑content assays evaluate the health, function, and responses of iPSC‑derived RPE cells, while the high‑throughput format provides an automated, reproducible system for assessing potential therapeutic compounds.
Our team is a dedicated group of experts that range across our sites, in Cambridge, Roslin, Newcastle and Grasse. We bring an innovative approach to advancing research and drug development for retinal diseases, leveraging the diverse expertise and approaches across these sites. Many members of our team are recognised as scientific leaders in their fields. Our customers can leverage their experience to accelerate their programs of work.
When you collaborate with Axol Bioscience, you gain access to a tailored approach that supports your research every step of the way. From the start, we facilitate open communication with our iPSC experts, ensuring that your project is guided by decades of experience.